Bioinformatics

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

BenevolentAI Appoints New Chief Technology Officer

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Health Technology, Professional Services, Machine learning, EBI, Elsevier, Bioinformatics, Drug discovery, University of Edinburgh, Artificial intelligence, Benevolence, AI, Doctor of Philosophy, Engineering, BAI, Family, Euronext Amsterdam, European

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.
  • The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer.
  • As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.
  • Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
    Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI.

Metabolon Unveils New Integrated Bioinformatics Platform

Retrieved on: 
Thursday, February 29, 2024
Acquisition, PCA, Research, Lens, Edith Cowan University, Metabolomics, Bioinformatics, Biomarker, Principal component analysis, Medicine, Biology, Pharmaceutical industry

MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced at Biomarkers UK the launch of its latest innovation: an integrated bioinformatics platform, advancing the landscape for metabolomics analysis in life sciences research.

Key Points: 
  • Partial Least Squares–Discriminant Analysis (PLS-DA): Facilitates the interpretation of complex datasets, enabling the identification of distinctive biomarkers that drive group separation.
  • "Metabolon has developed a solid, scalable solution to the non-trivial problem of metabolomics biochemical interpretation, specifically tailored to their world-leading data acquisition platform.
  • Metabolon's new bioinformatics platform alleviates much of this manual burden, with client data pre-populated and ready for analysis, accelerating discovery with publication-ready charts, plots, data tables, and insights.
  • "Metabolon is thrilled to unveil this groundbreaking bioinformatics platform, marking a significant leap forward in metabolomics research," said Dr. Ray Moran, Senior Director of Bioinformatics at Metabolon.

Metabolon Unveils New Integrated Bioinformatics Platform

Retrieved on: 
Thursday, February 29, 2024
Acquisition, PCA, Research, Lens, Edith Cowan University, Metabolomics, Bioinformatics, Biomarker, Principal component analysis, Medicine, Biology, Pharmaceutical industry

MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced at Biomarkers UK the launch of its latest innovation: an integrated bioinformatics platform, advancing the landscape for metabolomics analysis in life sciences research.

Key Points: 
  • Partial Least Squares–Discriminant Analysis (PLS-DA): Facilitates the interpretation of complex datasets, enabling the identification of distinctive biomarkers that drive group separation.
  • "Metabolon has developed a solid, scalable solution to the non-trivial problem of metabolomics biochemical interpretation, specifically tailored to their world-leading data acquisition platform.
  • Metabolon's new bioinformatics platform alleviates much of this manual burden, with client data pre-populated and ready for analysis, accelerating discovery with publication-ready charts, plots, data tables, and insights.
  • "Metabolon is thrilled to unveil this groundbreaking bioinformatics platform, marking a significant leap forward in metabolomics research," said Dr. Ray Moran, Senior Director of Bioinformatics at Metabolon.

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Retrieved on: 
Tuesday, February 6, 2024
Marker beacon, Manuscript, Bioinformatics, Peptide, Weill Cornell Medicine, Research, Genetic variation, Nature Communications, Cardiovascular disease, Gene, Nanoparticle, Proteome, Metabolomics, GIP, Drug discovery, Mass spectrometry, Protein, Medicine, Biophysics, Proteomics, Physiology, Plasma

REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci (pQTL) studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution.

Key Points: 
  • The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV.
  • Most MS-PAVs were aligned with known genetic markers (cis-pQTLs), validating the target specificity of the method.
  • Seer's approach provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
  • “At Seer, we offer researchers a new method for pQTL mapping and a deeper understanding of proteins and peptides for large-scale proteogenomic studies.”

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

Sarah McGarry, M.D., Senior FDA Official in CDER and CBER, Joins Greenleaf Health

Retrieved on: 
Wednesday, November 8, 2023
FDA, COVID-19, Public Policy, Consulting, Pharmaceutical, Professional Services, Medical Devices, Infectious Diseases, Government, Science, Biotechnology, AIDS, Other Science, Health, Research, Georgetown University School of Medicine, Bioinformatics, CBER, Center for Biologics Evaluation and Research, Policy, Food, Infection, Duke University, SARS-CoV-2, Center for Drug Evaluation and Research, OND, HIV, CDER, Ritonavir, Senior, Marketing, Internal medicine, China Biologic Products, Associate, Food and Drug Administration, Pharmaceutical industry

Greenleaf Health, Inc. (Greenleaf), a leading consulting firm for companies regulated by the Food and Drug Administration (FDA), is pleased to announce that Sarah McGarry, M.D., has joined as Senior Vice President, Drug and Biological Products.

Key Points: 
  • Greenleaf Health, Inc. (Greenleaf), a leading consulting firm for companies regulated by the Food and Drug Administration (FDA), is pleased to announce that Sarah McGarry, M.D., has joined as Senior Vice President, Drug and Biological Products.
  • Throughout her 18-year FDA service, Sarah held multiple leadership, review, and advisory positions within the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
  • Her knowledge of the FDA review process and regulatory policy will enrich the strategic and scientific guidance that Greenleaf provides to clients.
  • from Georgetown University Medical School and completed a residency in internal medicine and a fellowship in infectious diseases at Duke University.

AI in Biomedical Research: Regulatory & Technology Perspectives, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 17, 2023
Knowledge, Doctor of Philosophy, Division, Life, Machine learning, Research, CSO, AI, Animal, VMD, Artificial intelligence, FDA, National Center for Toxicological Research, Bioinformatics, Patient, Artifact, Medical device, Biostatistics

TORONTO, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the use of artificial intelligence (AI) and machine learning (ML) in preclinical drug research and related regulatory frameworks. The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations. On the one hand, legislative priorities seek to reduce the cost of healthcare and drugs, while also reducing the burden of testing on animals through the use of technology like AI.

Key Points: 
  • Attendees will learn best practice considerations for researchers considering, or already implementing AI techniques in their workflows.
  • TORONTO, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into the use of artificial intelligence (AI) and machine learning (ML) in preclinical drug research and related regulatory frameworks.
  • The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations.
  • The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations.

FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Research, Software, Artificial Intelligence, Genetics, Science, Patent, FOXO, NYSE, Intelligence, AI, DNA, Interim, Artificial intelligence, Longevity, Bioinformatics, Life, Quality of life, Pharmaceutical industry

Previously, the USPTO had issued Notices of Allowance to the Company for two related patents and the Company awaits Issue Notification for the second allowed patent.

Key Points: 
  • Previously, the USPTO had issued Notices of Allowance to the Company for two related patents and the Company awaits Issue Notification for the second allowed patent.
  • The first patent, for which the Company has received an Issue Notification, aids in practical applications of the technology that include generating epigenetic biomarkers.
  • On occasion, epigenetic data may be missing or unreliable because a specific DNA site may not have been assayed or was unreliably measured.
  • The patent allows the use of machine learning estimators to “fill in” the missing or unreliable epigenetic values at specific loci.

Abaxx Provides Corporate Update

Retrieved on: 
Friday, September 29, 2023
Carbon, RMO, Money, IDB, Risk, Partnership, Indian stock exchange, Electron capture, Metal, Article Six, Debenture, Engineering, AHC, CAD, Exchange, ACH, MAS, Monetary Authority of Singapore, USD, Bioinformatics, System Center Operations Manager, APPEC, Osaka Gas, Investment Exchanges and Clearing Houses Act 2006, Offering, Finance Secretary (India), RWE, Podcast, Growth, Bank, Micro ISV, Silver, News, NEO, Conference, Legislation, Security (finance), Clearing house, PetroChina, LNG, Vitol

TORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (NEO:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of the Abaxx Commodity Exchange and Clearinghouse (“Abaxx Singapore”), and producer of the SmarterMarkets™ Podcast, summarizes development activities over the past quarter and the general progress of the Company’s business plans. Abaxx also announces that it completed a financing of approximately CAD $1,013,000 through the private placement of an unsecured convertible debenture of the Company with an existing shareholder. Further details of these updates are provided below.

Key Points: 
  • Strategic Financing: The strategic financing process for Abaxx Singapore is progressing, with an expected conclusion in early Q4.
  • Abaxx has signed non-binding term sheets as well as definitive agreements with corporate strategic investors, as previously disclosed on August 14th, 2023.
  • The following press release provides a detailed update on these developments.
  • First Tranche of Strategic Financing: Abaxx Singapore, consistent with its initiative for a US$20 million to US$35 million best efforts equity private placement of preferred shares (the “Preferred Shares”) of Abaxx Singapore (the “Offering”), has formalized an investment agreement with an initial corporate investor.